OFG
AXDX

Oxford Financial Group’s Accelerate Diagnostics AXDX Stock Holding History

Oxford Financial Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,192
Closed -$318K – 217
2020
Q4 		$318K Hold
4,192
– – 0.05% 143
2020
Q3 		$447K Hold
4,192
– – 0.07% 101
2020
Q2 		$635K Hold
4,192
– – 0.11% 80
2020
Q1 		$349K Buy
+4,192
New +$590K 0.07% 106

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Oxford Financial Group's AXDX Position: Q1 2021 in Review

Oxford Financial Group sold out of Accelerate Diagnostics (AXDX) in Q1 2021, closing a stake of 4,192 shares — an estimated $318K sold.

Oxford Financial Group first reported a position in AXDX in Q1 2020 and held it in 4 quarters. The position peaked at $635K in Q2 2020. 99 funds tracked by Wall St. Rank hold AXDX as of Q1 2021.

  • Oxford Financial Group reported no remaining Accelerate Diagnostics position as of Q1 2021 after selling out during the quarter.
  • Oxford Financial Group sold 4,192 Accelerate Diagnostics shares in Q1 2021, an estimated $318K.
  • Oxford Financial Group first reported a position in Accelerate Diagnostics in Q1 2020 and held it in 4 quarters.
  • Oxford Financial Group's Accelerate Diagnostics position peaked at $635K in Q2 2020.
  • 99 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2021.

Based on Oxford Financial Group's 13F filing for Q1 2021, filed 10 May 2021.